13th Oct 2015 10:03
LONDON (Alliance News) - Ergomed PLC and Swedish drug development company Dilaforette AB Tuesday said the first patient has been enrolled in a phase II study of sevuparin in patients with sickle-cell disease.
The study is being conducted under a co-development deal between the two companies, under which Ergomed will co-invest a proportion of its revenue from the clinical and regulatory activities of the trial in return for an equity stake in Dilaforette.
"As our first co-development agreement in orphan drug development, we are very pleased to see the first patient recruited into the trial. The start of the study is an exciting milestone for Ergomed and our collaboration with Dilaforette reaffirms our commitment to developing drugs for rare diseases," said Chief Executive Officer Miroslav Reljanovic in a statement.
Shares in Ergomed were untraded Tuesday morning. It last closed at 157.00 pence.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
ERGO.L